drugset / Trial / NCT00607841
A Study of Ispinesib in Metastatic Breast Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The Phase I portion was a dose-escalation study designed to assess safety and tolerability in patients with metastatic breast cancer. Phase II was intended to measure response rate in patients with metastatic breast cancer but did not enroll because the Phase I portion was halted prior to Maximum Tolerated Dose (MTD) determination.
Timeline
- Start
- 2007-12
- Primary completion
- 2009-11
- Completion
- 2009-11
Outcome
Outcome not reported
Stopped: “Trial stopped for administrative reasons prior to official determination of MTD.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ispinesib | Unknown | 10 mg/m2 | Intravenous |
| Subject | ispinesib | Unknown | 12 mg/m2 | Intravenous |
| Subject | ispinesib | Unknown | 14 mg/m2 | Intravenous |